The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis

Osteoarthritis, Knee Clinical Trial

Official title:

A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03383081
• Other study ID #: SCLnow-XY-02
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2018
• Est. completion date: June 30, 2025

Study information

• Verified date: April 2024
• Source: Sclnow Biotechnology Co., Ltd.
• Contact: Lei Guo
• Phone: 861064368977
• Email: georgeguo[@]sclnow.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease

Description:

This is a random, open label, and parallel controled experiment. All patients are selected and sign consent forms, then divided into 3 groups. Doctors collect the basic information of patient. All patients receive laboratory and image examination as baseline. Then, they will give cell treatment based on the clinical protocol. Doctors have follow-up visit on 2 weeks, 1, 2, 3, 6, and 12 months after treatment, and do safety and efficacy evaluation.

Safety evaluation. Researcher collect all examination data of patients and compare with each groups. The safety tests including blood routine, urine routine, hepatorenal function, C reactive protein, erythrocyte sedimentation rate, and tumor marker, etc.

Efficacy evaluation. Based on Lysholm, the international knee documentation committee (IKDC) knee evaluation form, and Visual Analogue Scale/Score (VAS) to examine the change/improvement of knee joint function. By Magnetic Resonance Imaging (MRI) examination, grade patients with Kellgren-Lawrence Grading Scale, Assessment of Preoperative Cartilage Defect Severity (AMADEUS), and observe the change/improvement of patient.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 30, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified with Grade 2-3

• Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR (Magnetic Resonance)

• Age <70, no serious organ dysfunction

• Over 2 years knee pain or no very effective with conservative treatments

• Knee pain of VAS (visual analog scale score) is 4 or higher

• Normal hepatic and renal function, no history of gout, rheumatoid arthritis, and autoimmune diseases, etc.

• Understand and sign the consent form of this study

Exclusion Criteria:

• Refuse to sign the consent form, or cannot keep follow-up visit

• Age >70; Age <70, but with multiple organ failure

• Unstable vital signs (breath, blood pressure, pulse)

• Combined with knee ligament (anterior and the posterior cruciate ligament, medial and lateral collateral ligament) rupture, laxity, etc.

• Serious bleeding tendency, poor coagulation function (PTA <35%)

• Pregnant or breast feeding women, or positive pregnancy test in 7 days before treatment

• Participate other clinical experiments in 3 months

• With progressing malignant tumor

• Combined with shock and critically ill patients

• With mental disease, cannot

• With history of knee joint infection, surgery, and radiotherapy

• With immunosuppressive agents treatment in 6 weeks

• Injection with hormones and sodium hyaluronate in joint in 3 months

• Overweight expressed as body mass index (BMI) >35

• With skin disease around knee joint

• With Immunodeficiency disease, including long term use immunosuppressive agents patients

• Combined with serious infection

• With some other conditions that doctor propose not to participate

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Biological:
• Low dose mesenchymal stem cells
Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml);
• High dose mesenchymal stem cells
Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml)

Procedure:
• Intraarticular injection
Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group

Locations

Country	Name	City	State
China	Xiangya Hospital Central South University	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Sclnow Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kellgren-Lawrence Grading Scale	Using Magnetic Resonance Imaging (MRI) examination, and based on the images of bilateral knee joint, grade by Kellgren-Lawrence Grading Scale. Kellgren-Lawrence Grading Scale is a method of classifying the severity of knee osteoarthritis (OA).; Grade 0: No radiographic features of osteoarthritis; Grade 1: Possible joint space narrowing (normal joint space is at least 2 mm at the superior acetabulum) and osteophyte formation; Grade 2: Definite osteophyte formation with possible joint space narrowing; Grade 3: Multiple osteophytes, definite joint space narrowing, sclerosis and possible bony deformity; Grade 4: Large osteophytes, marked joint space narrowing, severe sclerosis and definite bony deformity.	12 months
Secondary	Assessment of Preoperative Cartilage Defect Severity (AMADEUS)	Using Magnetic Resonance Imaging (MRI) examination to diagnose patients by Assessment of Preoperative Cartilage Defect Severity (AMADEUS).	12 months
Secondary	Lysholm scoring	Using Lysholm Knee Scoring Scale to grade the knee function of patients, and examine the changes or improvement compare to baseline.	12 months
Secondary	The international knee documentation committee (IKDC) knee evaluation form	The international knee documentation committee knee evaluation form is used to assess the knee function of patients, examine the changes or improvement compare to baseline.	12 months
Secondary	Visual Analogue Scale/Score(VAS)	Using Visual Analogue Scale/Score for pain to examine the change/improvement of knee joint function.	12 months